Systemic sclerosis trial design moving forward

Journal of Scleroderma and Related Disorders

Volumn 1, Issue 2, 2016, Pages 177-180

  Johnson, Sindhu R ^a   Khanna, Dinesh ^b   Allanore, Yannick ^c   Matucci Cerinic, Marco ^d   Furst, Daniel E ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b Division of Rheumatology   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bayesian; Cross over trial; Enriched enrollment randomized withdrawal design; Randomized controlled trials; Randomized placebo phase design; Scleroderma

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID; TOCILIZUMAB; WARFARIN;

BAYES THEOREM; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; PSYCHOMETRY; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC SCLEROSIS;

EID: 85014276247     PISSN: 23971983     EISSN: 23971991     Source Type: Journal    
DOI: 10.5301/jsrd.5000198     Document Type: Review

References (27)

1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47.
2. Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the ‘many faces’ of systemic sclerosis. Ann Rheum Dis. 2013;72(3):319-21.
3. Furst DE, Pope JE, Seibold JR, et al. Progress and priorities in systemic sclerosis: the next 10 years – report from the World Scleroderma Foundation. Journal of Scleroderma and Related Disorders. 2016;1(1):7-9.
4. Abrahamyan L, Diamond IR, Johnson SR, Feldman BM. A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol. 2014;21(1):e66-78.
5. Pope JE, Khanna D, Johnson SR, Clements P. Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. Arthritis Care Res (Hoboken). 2012;64(7):955-9.
6. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763-9.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-44.
8. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-24.
9. Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. J Rheumatol. 2007;34(5):1125-32.
10. Streicher K, Morehouse CA, Groves CJ, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol. 2014; 66(1):173-84.
11. Jordan S, Distler J, Maurer B, et al. Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. Journal of Scleroderma and Related Disorders. 2016;1(2):220-225.
12. Furst D, Khanna D, Matucci-Cerinic M, et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol. 2007;34(5):1194-200.
13. Johnson SR, Hawker GA, Davis AM. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum. 2005;53(2): 256-62.
14. Khanna D, Lovell DJ, Giannini E, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis. 2008;67(5):703-9.
15. Abrahamyan L, Diamond IR, Johnson SR, Feldman B. A new toolkit for conducting clinical trials in rare disorders. J Popul Ther Clin Pharmacol. 2014;21(1):e66-e78.
16. Halpern SD, Ubel PA, Berlin JA, Townsend RR, Asch DA. Physicians’ preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. J Gen Intern Med. 2002;17(9): 689-95.
17. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol. 2002;31(1):140-9.
18. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol. 2008;66(2):266-75.
19. Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol. 2001;54(6):550-7.
20. Abrahamyan L, Li CS, Beyene J, Willan AR, Feldman BM. Survival distributions impact the power of randomized placebophase design and parallel groups randomized clinical trials. J Clin Epidemiol. 2011;64(3):286-92.
21. Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol. 2009;62(1):13-21e5.
22. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol. 2010;63(4):355-69.
23. Johnson SR, Granton JT, Tomlinson GA, et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol. 2012;39(2):276-85.
24. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57-65.
25. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol. 2009;36(2): 323-9.
26. Guyatt GH, Heyting A, Jaeschke R, Keller J, Adachi JD, Roberts RS. N of 1 randomized trials for investigating new drugs. Control Clin Trials. 1990;11(2):88-100.
27. Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol. 2010;63(12):1312-23.